uniQure (NASDAQ:QURE) Hits New 1-Year High on Analyst Upgrade

uniQure (NASDAQ:QURE)’s share price reached a new 52-week high during trading on Tuesday after Raymond James upgraded the stock from an outperform rating to a strong-buy rating. Raymond James now has a $52.00 price target on the stock, up from their previous price target of $20.00. uniQure traded as high as $17.39 and last traded at $15.30, with a volume of 61370594 shares traded. The stock had previously closed at $7.30.

A number of other equities research analysts have also issued reports on QURE. Royal Bank of Canada cut their target price on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. The Goldman Sachs Group cut their price objective on uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of uniQure in a research report on Wednesday, November 6th. StockNews.com upgraded uniQure to a “sell” rating in a report on Thursday, October 17th. Finally, Cantor Fitzgerald raised their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $27.33.

Insider Buying and Selling at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.74% of the stock is owned by company insiders.

Institutional Trading of uniQure

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of uniQure by 11.4% in the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after purchasing an additional 109,740 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of uniQure in the 2nd quarter worth $79,000. Clear Harbor Asset Management LLC raised its position in shares of uniQure by 35.2% during the second quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 12,500 shares during the period. Assenagon Asset Management S.A. purchased a new stake in shares of uniQure during the second quarter valued at $815,000. Finally, Privium Fund Management B.V. boosted its position in shares of uniQure by 10.6% in the 2nd quarter. Privium Fund Management B.V. now owns 640,416 shares of the biotechnology company’s stock valued at $2,869,000 after purchasing an additional 61,501 shares during the period. Institutional investors own 78.83% of the company’s stock.

uniQure Price Performance

The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The stock has a market cap of $745.72 million, a PE ratio of -3.08 and a beta of 0.89. The stock has a 50 day moving average of $6.42 and a two-hundred day moving average of $6.15.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million during the quarter, compared to the consensus estimate of $2.73 million. Equities analysts anticipate that uniQure will post -3.74 EPS for the current year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.